Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

While drugs like Keytruda are often described as breakthroughs, the study shows that their price places them far beyond the reach of the majority of patients who may need them.

The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.

A landmark study by onco-researchers at Tata Memorial Centre has laid bare the brutal arithmetic of modern cancer care. The ...

Merck (NYSE:MRK) is restructuring its pharmaceutical business into two divisions, Oncology and Specialty/Pharma & Infectious ...

Synthekine has entered a clinical trial partnership and supply agreement with Merck (MSD) to investigate STK-012 in combination with Keytruda (pembrolizumab) and chemotherapy in patients with ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

On February 20, Barclays started coverage of Merck & Co., Inc. (NYSE:MRK) with an Overweight rating. It set a $140 price ...

The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.

Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...